United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - irbesartan - tablet - 150mg

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - irbesartan 150mg - film coated tablet - 150 mg - active: irbesartan 150mg excipient: colloidal silicon dioxide hypromellose   isopropyl alcohol lactose monohydrate macrogol 6000 magnesium stearate methylene chloride microcrystalline cellulose polysorbate 80 purified water sodium starch glycolate - indicated for the treatment hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - irbesartan 150mg - film coated tablet - 150 mg - active: irbesartan 150mg excipient: colloidal silicon dioxide hypromellose   isopropyl alcohol lactose monohydrate macrogol 6000 magnesium stearate methylene chloride microcrystalline cellulose polysorbate 80 purified water sodium starch glycolate - indicated for the treatment hypertension.

Malta - English - Malta Medicines Authority

accord healthcare limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - irbesartan - film-coated tablet - irbesartan 150 mg - agents acting on the renin-angiotensin system

United Kingdom - English - myHealthbox

brown & burk uk ltd - irbesartan - film-coated tablets - 150mg - angiotensin-ii antagonists, plain - it is indicated in adults for the treatment of essential hypertension. it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; silicon dioxide; hypromellose; carnauba wax; lactose monohydrate; croscarmellose sodium; titanium dioxide; macrogol 3000 - karvea is indicated for the treatment of hypertension. karvea is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (more than or equal to 30 mg per 24 hour) or urinary protein in excess of 900 mg per 24 hours

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.